Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2009
10/14/2009CN101558169A Treatment of pigs with PCV2 antigen
10/14/2009CN101558150A In vitro cultivation of helicobacter species
10/14/2009CN101558082A Targeted binding agents directed to PDGFR-alpha and uses thereof
10/14/2009CN101557825A Proteolysis resistant antibody preparations
10/14/2009CN101557824A Method for production of live smallpox vaccine
10/14/2009CN101557823A Human endogenous retrovirus polypeptide compositions and methods of use thereof
10/14/2009CN101557822A Vaccin against group a beta hemolytic streptococcus and respective process for obtaining thereof
10/14/2009CN101557821A Conjugates of plasmodium falciparum surface proteins as malaria vaccines
10/14/2009CN101555483A Echinococcus granulosus EgFABP-Eg95 polypeptide and preparation and application of recombinant brevibacterium vaccine thereof
10/14/2009CN101555477A Heavy and light chain variable region gene of monoclonal antibody resisting human amyloid
10/14/2009CN101555468A Viral variants with altered susceptibility to nucleoside analogs and uses thereof
10/14/2009CN101555283A Antibodies to non-functional p2x7 receptor, diagnosis and treatment of cancers and other conditions
10/14/2009CN101555281A Preparation method of anti-influenza A H1N1 virus specific IgY and related formulation thereof
10/14/2009CN101554480A Improved DNA vaccines for production-type animals
10/14/2009CN101554477A Aftosa vaccine immunopotentiator
10/14/2009CN101554476A Aftosa vaccine immunopotentiator
10/14/2009CN100549027C Protein NMB0928 and use thereof in pharmaceutical formulations
10/14/2009CN100549021C Cynomolgus prostate specific antigen
10/14/2009CN100548386C Releasable polymeric conjugates based on biodegradable linkers
10/14/2009CN100548385C Brucellosis nucleic acid vaccine
10/14/2009CN100548384C Genetic engineering polypeptide vaccine adjuvant for aftosa, preparation method and application thereof
10/14/2009CN100548377C Vaccine composition containing modified dendritic cells
10/14/2009CN100548374C Combination therapy with class III anti-CEA monoclonal antibodies and therapeutic agents
10/14/2009CN100548373C Vaccines
10/14/2009CN100548275C Virosome-like-particles
10/13/2009US7601825 Administering to cancer cells a vector that encodes a single chain monoclonal antibody that immunospecifically binds to an 121P1F1-related protein
10/13/2009US7601818 Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
10/13/2009US7601817 For treating a disease medicated by TNF alpha including acute and chronic immune and immunoregulatory disorders and rheumatoid or osteo-arthritis
10/13/2009US7601815 For controlling development, differentiation, trafficking, and physiology of mammalian cells; diagnosis
10/13/2009US7601813 Anti-GL50 antibodies
10/13/2009US7601811 Bacillus thuringiensis gene with lepidopteran activity
10/13/2009US7601809 hematopoietic cytokine receptor polypeptide encoded by nucleotides equences for use in the treatment of cancer; restoring normal blood cell levels in patients suffering from anemia, thrombocytopenia, and neutropenia or receiving chemotherapy for cancer; biodrugs
10/13/2009US7601804 immunogens for treating cattle diseases; biodrugs for veterinary medicine
10/13/2009US7601801 polypeptide with binding to antigen and is recognized by cytotoxic T lymphocytes; use as cancer vaccine
10/13/2009US7601740 urea substituted piperidine derivatives; may confer antipsychotic and anti-dyskinetic efficacy in humans; use as novel therapeutics, sometimes in conjunction with other therapeutics, for Parkinson's Disease, related human neurodegenerative diseases, and psychosis
10/13/2009US7601698 Polypeptide
10/13/2009US7601697 Polypeptides; nucleic acid molecules and viral vectors which direct gene expression of such polypeptides; vaccines; genetic engineering; transfecting cells of animal ex vivo with nucleic acid molecule and delivering transfected cells animal
10/13/2009US7601531 Chlamydia pneumoniae polynucleotides and uses thereof
10/13/2009US7601514 Encodes a polypeptide which inhibits the proliferation of T-lymphocytes; use in diagnosis and treatment of immune disorders; PRO polypeptides; autoimmune disorders
10/13/2009US7601508 Ecdysone receptor polypeptide from the homopteran whitefly (Bamecia argentifoli, BaEcR) use screening for monoclonal antibodies; biological insecticides
10/13/2009US7601359 Compositions and methods for the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress proteins
10/13/2009US7601358 Mycobacterium tuberculosis protein composition
10/13/2009US7601357 Targeting of long chain triacylglycerol hydrolase gene for tuberculosis treatment
10/13/2009US7601356 Methods and compositions for increasing replication capacity of an influenza virus
10/13/2009US7601355 Compositions and methods for altering immune function
10/13/2009US7601354 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
10/13/2009US7601353 Peptide-based passive immunization therapy for treatment of atherosclerosis
10/13/2009US7601352 Monoclonal antibodies and antigen binding fragments thereof capable of binding TrkA and inhibiting the functional activation of TrkA
10/13/2009US7601351 Antibodies against protective antigen
10/13/2009US7601350 Antibodies that bind M. tuberculosis polypeptides
10/13/2009US7601349 GIPs, a family of polypeptides with transcription factor activity that interact with Goodpasture antigen binding protein
10/13/2009US7601348 Analyzing distribution of GlcNAc-6-sulfotransferase isozymes, sulfation enzymes of sugar residues; immunoassay
10/13/2009US7601347 Methods and compositions for controlled release of bioactive compounds
10/13/2009US7601343 An isolated RNA-pulsed antigen presenting cell comprising tumor specific RNA; stimulation of cytotoxic T-lymphocyte proliferation ex vivo or in vivo for adoptive immunotherapy; anticarcinogenic agents; antitumor agents; bactericides; viricides
10/13/2009US7601342 Producing a substantially pure cytotoxic population of educated, antigen-specific immune effector cells as adoptive immunostimulants;using hybrid cells generated by fusion of a dendritic cell and a tumor or cancer cell that expresses cell-surface antigens; antitumor agents; anticarcinogenic agents
10/13/2009US7601332 Vitamin receptor binding drug delivery conjugates
10/13/2009CA2333598C Toxoplasma gondii antigens, p35, and uses thereof
10/13/2009CA2236888C Medicament, in particular for modulation of the immune response in the control of viruses, tumors, bacteria and parasites
10/13/2009CA2234263C Pharmaceutical composition for treating papillomavirus tumours and infection
10/13/2009CA2224413C Immunovectors for the intracellular and intranuclear transport
10/13/2009CA2222650C Tnf-.alpha. converting enzyme
10/13/2009CA2222513C Agents binding specifically to biotin for detecting damaged nucleic acid bases
10/13/2009CA2220339C Toxin conjugates having a spacer comprising polyalkylene glycol and peptide
10/13/2009CA2215933C Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
10/13/2009CA2154488C Ganglioside-klh conjugate vaccines with qs-21
10/08/2009WO2009124294A2 Pharmaceutical compositions for binding sphingosine-1-phosphate
10/08/2009WO2009124281A2 Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis
10/08/2009WO2009124189A1 Non-invasive systems and methods for in-situ photobiomodulation
10/08/2009WO2009124109A1 Human monoclonal antibodies specific for cd22
10/08/2009WO2009123894A2 Her2/neu-specific antibodies and methods of using same
10/08/2009WO2009123759A2 Therapeutic uses of biocompatible biogel compositions
10/08/2009WO2009123480A1 Anti-infective agents and uses thereof
10/08/2009WO2009123188A1 Partial peptide of survivin presented on mhc class ii molecule and use thereof
10/08/2009WO2009123145A1 Parasporin-1 receptor and use thereof
10/08/2009WO2009123119A1 Antigen-and-drug vehicle comprising synthetic peptide, and mucosal vaccine using the same
10/08/2009WO2009122667A1 Therapeutic for hepatic cancer
10/08/2009WO2009121845A2 Overlapping peptides from variable antigens, t cell populations and uses thereof
10/08/2009WO2009121690A1 Agent for treating disease
10/08/2009WO2009121238A1 A composition and method for auto-treating tumors
10/08/2009WO2009121162A1 Assay for soluble cd200
10/08/2009WO2009101205A3 Immunogenic control of tumours and tumour cells
10/08/2009WO2009101204A3 Elimination of immune responses to viral vectors
10/08/2009WO2009094006A3 Bordetella outer-membrane protein antigens and methods of making and using the same
10/08/2009WO2009092052A3 Methods and compositions for treating polyps
10/08/2009WO2009091692A3 Malaria vaccine compositions and constituents which elicit cell mediated immunity
10/08/2009WO2009089399A3 Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection
10/08/2009WO2009088950A3 Pcv2 orf2 virus like particle with foreign amino acid insertion
10/08/2009WO2009087175A3 Allergy vaccine composition for mucosal administration
10/08/2009WO2009080806A3 Modified influenza virus
10/08/2009WO2008104385A8 Method for the treatment of amyloidoses
10/08/2009US20090255004 G-Protein Coupled Receptor and Uses Therefor
10/08/2009US20090255001 Parkinson's Disease-Related Gene GRK5 and Uses Thereof
10/08/2009US20090253645 Methods and materials for treating and preventing inflammation of mucosal tissue
10/08/2009US20090253185 Avipox recombinants expressing foot and mouth disease virus genes
10/08/2009US20090252795 Bioceramic scaffolds for tissue engineering
10/08/2009US20090252769 Preventive and therapeutic vaccine for storke and neurological disorders
10/08/2009US20090252766 Attenuated gram negative bacteria
10/08/2009US20090252765 Bacille calmette-guerin (bcg)-based anti-atheroma vaccine and methods of use thereof
10/08/2009US20090252764 Suture line administration technique using botulinum toxin
10/08/2009US20090252763 Biological adjuvants
1 ... 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 ... 1823